Oruka Therapeutics Inc. Common Stock vs Personalis Inc. Common Stock — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Personalis Inc. Common Stock trades at $16.07 (market cap $1.69B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 3.1× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Personalis Inc. Common Stock for 0 Days on average.
| ORKA | PSNL | |
|---|---|---|
Market Cap | $5.18B | $1.69B |
Volume | 490,798 | 3,817,236 |
Sector | Health | Health |
52-Week High | $113.08 | $18.38 |
52-Week Low | $26.19 | $5.04 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.31B | $1.52B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →